Nonhuman Primate Reagent Resource

非人类灵长类动物试剂资源

• 批准号: 10600024
• 负责人: Kathleen Engelman
• 金额: $ 177.5万
• 依托单位: UNIV OF MASSACHUSETTS MED SCH WORCESTER
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-29 至 2026-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10600024
• 关键词: Acceleration; Animal Model; Animals; Antibodies; Biological; Biological Markers; Biological Response Modifier Therapy; Biological Testing; Cells; Communicable Diseases; Communities; Community Outreach; Data; Databases; Development; Development Plans; Discipline; Disease; Disease model; Electronics; Engineering; Five-Year Plans; Formulation; Future; Goals; Human; Immune; Immunologics; Immunomodulators; Infrastructure; Methodology; Modeling; Monkeys; Monoclonal Antibodies; Names; Natural Killer Cells; Organ Transplantation; Pathogenesis; Peptide Hydrolases; Population; Production; Quality Control; Reaction; Reagent; Recombinant Antibody; Recombinants; Records; Research; Research Personnel; Resources; Role; Scientific Advances and Accomplishments; Services; Source; Technology; Translational Research; Vaccines; antibody detection; design; human disease; human model; immunoregulation; improved; in vivo; in-vitro diagnostics; large scale production; manufacture; next generation; nonhuman primate; novel; novel therapeutics; operation; outreach; pre-clinical; programs; response; tool; web site

Summary The Nonhuman Primate Reagent Resource (NHPRR) has 21 years of continuous operation providing specialized reagents to enable and enhance research with nonhuman primate (NHP) models of human disease. This application describes our next five-year plan to develop and distribute these essential NHP- tailored reagents. NHPs serve a crucial role in translational research, providing animal models for exploring the pathogenesis of infectious and noninfectious diseases, and for testing biological therapies and vaccines. Antibodies and biological reagents that target specific immune cells and biomarkers can be essential tools in determining disease mechanisms. Additionally, immunomodulators that can be studied in vivo serve as proof-of-concept for new therapies. While these crucial research tools are available for small animal and human studies, substantial gaps exist for validated NHP research reagents. To overcome this scarcity, for the past 21 years, the NHPRR has fulfilled critical needs within the scientific community by developing, manufacturing and distributing NHP-specific reagents for in vitro diagnostics and for in vivo use. Utilization of this resource has grown dramatically since this program’s inception. During the last five years (2015-2019), we fulfilled 2,821 reagent requests for 320 investigators and distributed ~2,500 grams of recombinant antibodies for administration to NHPs. By continuously availing ourselves of future scientific advances and technological improvements in antibody development, engineering, expression and vectoring, we will keep supporting the scientific community utilizing NHP models across all scientific disciplines.

总结 非人灵长类动物试剂资源（NHPRR）已连续运营21年， 专门的试剂，以实现和加强研究与非人灵长类动物（NHP）模型的人类 疾病此应用程序描述了我们的下一个五年计划，以开发和分发这些基本的NHP- 定制试剂 NHPs在转化研究中起着至关重要的作用，为探索 感染性和非感染性疾病的发病机理，以及用于测试生物疗法和疫苗。 针对特定免疫细胞和生物标志物的抗体和生物试剂可能至关重要 确定疾病机制的工具。此外，可以在体内研究的免疫调节剂 作为新疗法的概念验证。虽然这些关键的研究工具可用于小型 在动物和人类研究中，经验证的NHP研究试剂存在很大差距。克服 在过去的21年里，NHPRR满足了科学界的关键需求 通过开发、制造和分销用于体外诊断和体内诊断的NHP特异性试剂， 体内使用。自该方案开始以来，对这一资源的利用急剧增加。期间 过去五年（2015-2019），我们为320名研究者完成了2，821份试剂申请，并分发了 约2，500克重组抗体用于NHP给药。 通过不断利用未来的科学进步和技术进步， 抗体开发，工程，表达和载体，我们将继续支持科学 社区利用NHP模型在所有科学学科。